Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system

Neurobiology of Disease

Volumn 22, Issue 2, 2006, Pages 404-420

  Betarbet, Ranjita ^a   Canet Aviles, Rosa M ^b   Sherer, Todd B ^a   Mastroberardino, Pier G ^a,f   McLendon, Chris ^b   Kim, Jin Ho ^a   Lund, Serena ^a   Na, Hye Mee ^a,f   Taylor, Georgia ^a   Bence, Neil F ^c   Kopito, Ron ^c   Seo, Byoung Boo ^d   Yagi, Takao ^d   Yagi, Akemi ^d   Klinefelter, Gary ^e   Cookson, Mark R ^b   Greenamyre, J Timothy ^a,f  

^a Center for Neurodegenerative Disease   (United States)

^b National Institute of Aging   (United States)

^c STANFORD UNIVERSITY   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Tocopherol; Mitochondria; Oxidative stress; Pesticide; Proteasomal dysfunction

Indexed keywords

ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; PESTICIDE; PROTEASOME; ROTENONE; TOXIN; UBIQUITIN; DJ 1 PROTEIN, MOUSE; DJ-1 PROTEIN, MOUSE; INSECTICIDE; ONCOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; ENERGY METABOLISM; LEWIS RAT; MALE; METABOLISM; NERVE CELL; PARKINSONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX I; ENERGY METABOLISM; HUMANS; INSECTICIDES; MALE; MITOCHONDRIA; NERVE DEGENERATION; NEURONS; ONCOGENE PROTEINS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, INBRED LEW; ROTENONE; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UBIQUITIN;

EID: 33745612296     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2005.12.003     Document Type: Article

References (78)

1. Bai Y., Hajek P., Chomyn A., Chan E., Seo B.B., Matsuno-Yagi A., Yagi T., and Attardi G. Lack of complex I activity in human cells carrying a mutation in MtDNA-encoded ND4 subunit is corrected by the Saccharomyces cerevisiae NADH-quinone oxidoreductase (NDI1) gene. J. Biol. Chem. 276 (2001) 38808-38813
2. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 (2001) 1552-1555
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease [in process citation]. Nat. Neurosci. 3 (2000) 1301-1306
4. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. BioEssays 24 (2002) 308-318
5. Betarbet R., Poisik O., Sherer T.B., and Greenamyre J.T. Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Exp. Neurol. 187 (2004) 76-85
6. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
7. Braak H., Ghebremedhin E., Rub U., Bratzke H., and Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318 (2004) 121-134
8. Butterfield P.G., Valanis B.G., Spencer P.S., Lindeman C.A., and Nutt J.G. Environmental antecedents of young-onset Parkinson's disease. Neurology 43 (1993) 1150-1158
9. Canet-Aviles R.M., Wilson M.A., Miller D.W., Ahmad R., McLendon C., Bandyopadhyay S., Baptista M.J., Ringe D., Petsko G.A., and Cookson M.R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9103-9108
10. Conway K.A., Harper J.D., and Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4 (1998) 1318-1320
11. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
12. Dalfo E., Gomez-Isla T., Rosa J.L., Nieto Bodelon M., Cuadrado Tejedor M., Barrachina M., Ambrosio S., and Ferrer I. Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. J. Neuropathol. Exp. Neurol. 63 (2004) 302-313
13. Davies K.J. Degradation of oxidized proteins by the 20S proteasome. Biochimie 83 (2001) 301-310
14. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
15. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., and Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52 (1989) 381-389
16. Duda J.E., Giasson B.I., Mabon M.E., Lee V.M., and Trojanowski J.Q. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neurol. 52 (2002) 205-210
17. Farrer M., Destee T., Becquet E., Wavrant-De Vrieze F., Mouroux V., Richard F., Defebvre L., Lincoln S., Hardy J., Amouyel P., and Chartier-Harlin M.C. Linkage exclusion in French families with probable Parkinson' s disease. Mov. Disord. 15 (2000) 1075-1083
18. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease [see comments]. Nature 404 (2000) 394-398
19. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Busceti C.L., Ruffoli R., Soldani P., Ruggieri S., Alessandri M.G., and Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23 (2003) 8955-8966
20. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., and Sudhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and {alpha}-synuclein. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3413-3418
21. Ghee M., Fournier A., and Mallet J. Rat alpha-synuclein interacts with Tat binding protein 1 a component of the 26S proteasomal complex. J. Neurochem. 75 (2000) 2221-2224
22. Giasson B.I., and Lee V.M. Are ubiquitination pathways central to Parkinson's disease?. Cell 114 (2003) 1-8
23. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., and Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions [in process citation]. Science 290 (2000) 985-989
24. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., and Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50 (1998) 1346-1350
25. Greenamyre J.T., and Hastings T.G. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 304 (2004) 1120-1122
26. Greenamyre J.T., Betarbet R., and Sherer T.B. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat. Disord. 9 Suppl. 2 (2003) 59-64
27. Hoglinger G.U., Carrard G., Michel P.P., Medja F., Lombes A., Ruberg M., Friguet B., and Hirsch E.C. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 86 (2003) 1297-1307
28. Hoglinger G.U., Feger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., and Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84 (2003) 491-502
29. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M., and Masliah E. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157 (2000) 401-410
30. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13 (1998) 24-34
31. Kanda S., Bishop J.F., Eglitis M.A., Yang Y., and Mouradian M.M. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97 (2000) 279-284
32. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., and Bjorklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22 (2002) 2780-2791
33. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism [see comments]. Nature 392 (1998) 605-608
34. Ko L., Mehta N.D., Farrer M., Easson C., Hussey J., Yen S., Hardy J., and Yen S.H. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein [in process citation]. J. Neurochem. 75 (2000) 2546-2554
35. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., and Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. NeuroReport 11 (2000) 211-213
36. Krishnan S., Chi E.Y., Wood S.J., Kendrick B.S., Li C., Garzon-Rodriguez W., Wypych J., Randolph T.W., Narhi L.O., Biere A.L., Citron M., and Carpenter J.F. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 42 (2003) 829-837
37. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease [letter]. Nat. Genet. 18 (1998) 106-108
38. Lauwers E., Debyser Z., Van Dorpe J., De Strooper B., Nuttin B., and Baekelandt V. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 13 (2003) 364-372
39. Le Couteur D.G., McLean A.J., Taylor M.C., Woodham B.L., and Board P.G. Pesticides and Parkinson's disease. Biomed. Pharmacother. 53 (1999) 122-130
40. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., and Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 -> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8968-8973
41. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease [letter]. Nature 395 (1998) 451-452
42. Liu Y., Fallon L., Lashuel H.A., Liu Z., and Lansbury Jr. P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111 (2002) 209-218
43. Lotharius J., and Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev., Neurosci. 3 (2002) 932-942
44. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., and Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277 (2002) 1641-1644
45. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., and Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (2000) 1265-1269
46. McCutchen-Maloney S.L., Matsuda K., Shimbara N., Binns D.D., Tanaka K., Slaughter C.A., and DeMartino G.N. cDNA cloning, expression, and functional characterization of PI31 a proline-rich inhibitor of the proteasome. J. Biol. Chem. 275 (2000) 18557-18565
47. McNaught K.S., and Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297 (2001) 191-194
48. McNaught K.S., Belizaire R., Jenner P., Olanow C.W., and Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326 (2002) 155-158
49. McNaught K.S., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179 (2003) 38-46
50. McNaught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56 (2004) 149-162
51. Meiners S., Heyken D., Weller A., Ludwig A., Stangl K., Kloetzel P.M., and Kruger E. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes. J. Biol. Chem. 278 (2003) 21517-21525
52. Menegon A., Board P.G., Blackburn A.C., Mellick G.D., and Le Couteur D.G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms [see comments]. Lancet 352 (1998) 1344-1346
53. Mitsumoto A., and Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radical Res. 35 (2001) 885-893
54. Mitsumoto A., Nakagawa Y., Takeuchi A., Okawa K., Iwamatsu A., and Takanezawa Y. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radical Res. 35 (2001) 301-310
55. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., Trojanowski J.Q., Lee V.M., and Ischiropoulos H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21 (2001) 8053-8061
56. Pettus E.H., Betarbet R., Cottrell B., Wallace D.C., Madyastha V., and Greenamyre J.T. Immunocytochemical characterization of the mitochondrially encoded ND1 subunit of complex I (NADH: ubiquinone oxidoreductase) in rat brain. J. Neurochem. 75 (2000) 383-392
57. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease [see comments]. Science 276 (1997) 2045-2047
58. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease [letter] [see comments]. Lancet 1 (1989) 1269
59. Seo B.B., Wang J., Flotte T.R., Yagi T., and Matsuno-Yagi A. Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells. J. Biol. Chem. 275 (2000) 37774-37778
60. Seo B.B., Nakamaru-Ogiso E., Flotte T.R., Yagi T., and Matsuno-Yagi A. A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. Mol. Ther. 6 (2002) 336-341
61. Shamoto-Nagai M., Maruyama W., Kato Y., Isobe K., Tanaka M., Naoi M., and Osawa T. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J. Neurosci. Res. 74 (2003) 589-597
62. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., and Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22 (2002) 7006-7015
63. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
64. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
65. Sherman M.Y., and Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29 (2001) 15-32
66. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., and Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25 (2000) 302-305
67. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. {alpha}-synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
68. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., and Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278 (2003) 11753-11759
69. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies [letter]. Nature 388 (1997) 839-840
70. Sulzer D. Alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nat. Med. 7 (2001) 1280-1282
71. Taira T., Saito Y., Niki T., Iguchi-Ariga S.M., Takahashi K., and Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5 (2004) 430
72. Trojanowski J.Q., and Lee V.M. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch. Neurol. 55 (1998) 151-152
73. Uryu K., Giasson B.I., Longhi L., Martinez D., Murray I., Conte V., Nakamura M., Saatman K., Talbot K., Horiguchi T., McIntosh T., Lee V.M., and Trojanowski J.Q. Age-dependent synuclein pathology following traumatic brain injury in mice. Exp. Neurol. 184 (2003) 214-224
74. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., and Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
75. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., and Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74 (2000) 721-729
76. Yokata T., Sugawara K., Ito K., R T., Ariga H., and Mizusawa H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress and proteasome inhibition. Biochem. Biophys. Res. Commun. 312 (2003) 1342-1348
77. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., and Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13354-13359
78. Zhang L., Shimoji M., Thomas B., Moore D.J., Yu S.W., Marupudi N.I., Torp R., Torgner I.A., Ottersen O.P., Dawson T.M., and Dawson V.L. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 14 (2005) 2063-2073